MarketBeat
04 Jun 2026, 07:07 UTC · 15w ago
Verdict
Headline takes no side. We score ANNX +0.80 across five claims — strongly bullish.
+0.80strongly bullish
More positive than 86% of ticker scores this week
What the story claims
5 claims · scored −1 bearish … +1 bullish
Annexon expects phase III data for its geographic atrophy program in the fourth quarter of this year.
More positive than 99% of claims this week
The company has already filed for approval in Europe for its Guillain-Barré syndrome (GBS) program.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More positive than 86% of claims this week
Annexon plans to release data from the FORWARD study in GBS patients before the geographic atrophy readout.
More positive than 77% of claims this week
The company expects early data from its oral small-molecule complement program, ANX1502, in cold agglutinin disease later this year.
So whatEarly-stage data provides a proof-of-concept for a new modality (oral vs injectable), expanding the company's long-term valuation.
More positive than 64% of claims this week
Annexon expects to file a biologics license application (BLA) in the United States for GBS in 2026.
More positive than 51% of claims this week
Which stocks this story touches
More positive than 86% of ticker scores this week
The company highlighted a strong pipeline with positive phase II results and upcoming catalysts for geographic atrophy, GBS, and cold agglutinin disease.
More negative than 72% of ticker scores this week
Annexon CEO claimed that Iveric's approved therapies have not demonstrated visual protection in their programs.
More negative than 72% of ticker scores this week
Annexon CEO claimed that Apellis's approved therapies have not demonstrated visual protection in their programs.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Accesswire
14h ago
More positive than 57% of relationship scores this week
[mutual] Annexon competes with Iveric Bio in providing therapies for geographic atrophy.
−28.2%
Price is moving against the score
$3.87 vs $5.39 close before publication (Jun 3) · not market-adjusted
ANNX chart →
